Literature DB >> 15667493

Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?

Peter D R Higgins1, Marc Schwartz, John Mapili, Ellen M Zimmermann.   

Abstract

OBJECTIVES: Many disease activity indices are used to measure ulcerative colitis. Invasive indices incorporate an endoscopic score, while noninvasive indices do not require endoscopy. In clinical practice, many patients are treated based on their symptoms without endoscopic evaluation. However, invasive indices are commonly used in clinical research. Our objective was to determine whether endoscopy is necessary for the assessment of disease activity in patients with ulcerative colitis.
METHODS: Sixty-six consecutive ulcerative colitis patients were evaluated with invasive indices: the St. Mark's index and the Ulcerative Colitis Disease Activity Index (UCDAI); and noninvasive indices: the Simple Clinical Colitis Activity Index (SCCAI) and the Seo index. The correlations between the indices were measured. The contribution of the endoscopic items was measured with linear regression modeling. The overlap of endoscopy with other items in the standard indices was determined through factor analysis.
RESULTS: The two noninvasive indices correlated well with the invasive St. Mark's Index (SCCAI 0.86, Seo 0.70). After adjusting for the three noninvasive UCDAI items, the UCDAI endoscopy item predicted only 0.04% of the variance in the St. Mark's index. Factor analysis demonstrated that this is because the endoscopy items in the invasive indices correlate with stool frequency and stool blood items.
CONCLUSIONS: Endoscopy items contribute little additional information to indices of disease activity in ulcerative colitis. The clinical practice of treating patients based on reported symptoms is appropriate. The use of noninvasive indices in clinical trials could lower study costs and may increase subjects' willingness to participate.

Entities:  

Mesh:

Year:  2005        PMID: 15667493     DOI: 10.1111/j.1572-0241.2005.40641.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  26 in total

1.  Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis.

Authors:  L Keefer; T H Taft; J L Kiebles; Z Martinovich; T A Barrett; O S Palsson
Journal:  Aliment Pharmacol Ther       Date:  2013-08-19       Impact factor: 8.171

2.  Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario.

Authors:  Lee S Roth; Nilesh Chande; Terry Ponich; Maya L Roth; James Gregor
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

3.  The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial.

Authors:  Laurie Keefer; Jennifer L Kiebles; Monika A Kwiatek; Olafur Palsson; Tiffany H Taft; Zoran Martinovich; Terrence A Barrett
Journal:  Biol Res Nurs       Date:  2011-02-28       Impact factor: 2.522

4.  A new look at a mainstay ulcerative colitis therapy.

Authors:  Charles A Sninsky; Michael Safdi; Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-02

5.  Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study.

Authors:  Ignacio Marín-Jiménez; Pilar Nos; Eugeni Domènech; Sabino Riestra; Javier P Gisbert; Xavier Calvet; Xavier Cortés; Eva Iglesias; Jose M Huguet; Carlos Taxonera; Ramón Fernández; Daniel Carpio; Ana Gutiérrez; Jordi Guardiola; Luisa Castro Laria; Beatriz Sicilia; Luis Bujanda; Luis Cea-Calvo; Cristina Romero; Óscar Rincón; Berta Juliá; Julián Panés
Journal:  Am J Gastroenterol       Date:  2016-01-12       Impact factor: 10.864

Review 6.  Methotrexate for Inflammatory Bowel Diseases - New Developments.

Authors:  Hans H Herfarth
Journal:  Dig Dis       Date:  2016-03-16       Impact factor: 2.404

7.  Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis.

Authors:  Burton I Korelitz; Keith Sultan; Megha Kothari; Leo Arapos; Judy Schneider; Georgia Panagopoulos
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

8.  An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index.

Authors:  Meenakshi Bewtra; Colleen M Brensinger; Vesselin T Tomov; Tram B Hoang; Carly E Sokach; Corey A Siegel; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2014-06       Impact factor: 5.325

9.  Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN).

Authors:  Harald Matthes; Thomas Krummenerl; Manfred Giensch; Corinna Wolff; Jürgen Schulze
Journal:  BMC Complement Altern Med       Date:  2010-04-15       Impact factor: 3.659

10.  Racial differences in disease extent and severity in patients with ulcerative colitis: a retrospective cohort study.

Authors:  Mark H Flasar; Sandra Quezada; Priti Bijpuria; Raymond K Cross
Journal:  Dig Dis Sci       Date:  2008-02-14       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.